Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation

Eur J Med Res. 2024 Jan 3;29(1):19. doi: 10.1186/s40001-023-01621-6.

Abstract

Background: The biological behavior of low-grade glioma (LGG) is significantly affected by N6-methyladenosine (m6A) methylation, an essential epigenetic alteration. Therefore, it is crucial to create a prognostic model for LGG by utilizing genes that regulate m6A methylation.

Methods: Using TCGA and GTEx databases. We examined m6A modulator levels in LGG and normal tissues, and investigated PD-L1 and PD-1 expression, immune scores, immune cell infiltration, tumor immune microenvironment (TIME) and potential underlying mechanisms in different LGG clusters. We also performed immunohistochemistry and RT-qPCR to identify essential m6A adjustment factor.

Results: The results showed that m6A regulatory element expression was significantly increased in LGG tissues and was significantly associated with TMIE. A substantial increase in PD-L1 and PD-1 levels in LGG tissues and high-risk cohorts was observed. PD-L1 expression was positively correlated with FTO, ZCCHC4, and HNRNPD, whereas PD-1 expression was negatively correlated with FTO, ZC3H7B, and HNRNPD. The prognostic signature created using regulators of m6A RNA methylation was shown to be strongly associated with the overall survival of LGG patients, and FTO and ZCCHC4 were confirmed as independent prognostic markers by clinical samples. Furthermore, the results revealed different TIME characteristics between the two groups of patients, indicating disrupted signaling pathways associated with LGG.

Conclusion: Our results present that the m6A regulators play vital role in regulating PD-L1/PD-1 expression and the infiltration of immune cells, thereby exerting a sizable impact on the TIME of LGG. Therefore, m6A regulators have precise predictive value in the prognosis of LGG.

Keywords: Immune infiltrates; Low-grade glioma; N6-methyladenosine methylation; PD-1; PD-L1.

MeSH terms

  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO
  • B7-H1 Antigen*
  • Biomarkers, Tumor / genetics
  • Glioma* / genetics
  • Humans
  • Prognosis
  • Programmed Cell Death 1 Receptor
  • RNA Methylation
  • Tumor Microenvironment / genetics

Substances

  • 6-methyladenine
  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor
  • Biomarkers, Tumor
  • FTO protein, human
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO